Please assess the completion status of the following clinical trial:

Trial Title: L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Sickle cell disease (all genotypes)~2. Children, adolescents and young adults between ages 6 to 21 years~3. In a steady disease state and not in the midst of any acute complication other than VOC due to sickle cell disease at study entry~4. For female of childbearing potential, a negative urine pregnancy test and using an adequate method of contraception, or denies sexual activity~5. Subjects or parents or legal guardian of the subject who are willing and able to sign and provide consent and assent (where appropriate for the age of the child).~Exclusion Criteria:~1. Current pain lasting \>3 days~2. \>6 hospital admissions in the prior year~3. History of opioid dependence/substance abuse~4. Has been on a clinical trial of a new therapy for sickle cell disease within the last 3 months~5. Presence of any other complication related to sickle cell disease such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, renal dysfunction, dactylitis, acute chest syndrome and other major medical conditions or organ dysfunction~6. Severe anemia (hemoglobin \<6 g/dL)~7. History of red blood cell transfusion within the last 30 days~8. Systemic steroid therapy within the last 48 hours~9. Pregnancy or lactation (subjects must have a negative urine pregnancy test)~10. Serum creatinine levels:~    1. Age 6 to 13 years \>0.9 mg/dL~   2. Age 14 to 17 years \>1.0 mg/dL~   3. Age \>18 years \>1.5 mg/dL~11. Report of fever (\>38°C) within last 48 hours~12. Presence of acute chest syndrome, sepsis, bacterial infection, hemodynamic instability~13. Subjects with inability to have parental assent given (ages 6 to 17 years) or consent (ages 18 through 21 years).~    Note: Parents or legal guardians can provide consent for subjects who are unable to provide assent (eg, sleepy or preoccupied by their pain).~14. History of allergic reaction to L-citrulline product~15. Medications that are known to be contra-indicated with use of L-citrulline~16. History of diabetes.~17. Subjects with a baseline prothrombin time International Normalized ratio (INR) \>2.0.~18. Received any blood products within 3 weeks of the screening visit.~19. Unreliable venous access~20. The PI considers that the subject will be unable to comply with the study requirements.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (L-citrulline) (Type: ACTIVE_COMPARATOR): 25 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
- Arm 2 (L-citrulline) (Type: ACTIVE_COMPARATOR): 50 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
- Arm 3 (L-citrulline) (Type: ACTIVE_COMPARATOR): 100 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
- Arm 4 (L-citrulline) (Type: ACTIVE_COMPARATOR): 100 mg/kg bolus + 11 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
- Part 2 Arm 1 (L-citrulline) (Type: ACTIVE_COMPARATOR): Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. L-citrulline will be administered to the active arm.
- Part 2 Arm 2 D5 1/2NS (Type: PLACEBO_COMPARATOR): Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio.

Based on this trial design, predict the completion outcome and termination type (if applicable).